These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 25152580)

  • 1. Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts.
    Kruger S; Haas M; Ormanns S; Bächmann S; Siveke JT; Kirchner T; Heinemann V; Boeck S
    World J Gastroenterol; 2014 Aug; 20(31):10769-77. PubMed ID: 25152580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and predictive markers in pancreatic adenocarcinoma.
    Le N; Sund M; Vinci A;
    Dig Liver Dis; 2016 Mar; 48(3):223-30. PubMed ID: 26769569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment landscape of metastatic pancreatic cancer.
    De Dosso S; Siebenhüner AR; Winder T; Meisel A; Fritsch R; Astaras C; Szturz P; Borner M
    Cancer Treat Rev; 2021 May; 96():102180. PubMed ID: 33812339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial.
    Bachet JB; Chibaudel B; Bonnetain F; Validire P; Hammel P; André T; Louvet C;
    BMC Cancer; 2015 Oct; 15():653. PubMed ID: 26445094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.
    Shui L; Cheng K; Li X; Shui P; Zhou X; Li J; Yi C; Cao D
    BMC Cancer; 2020 Jul; 20(1):636. PubMed ID: 32646394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The absence of class III β-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients with unresectable pancreatic ductal adenocarcinoma.
    Kato A; Naiki-Ito A; Naitoh I; Hayashi K; Nakazawa T; Shimizu S; Nishi Y; Okumura F; Inoue T; Takada H; Kondo H; Yoshida M; Takahashi S; Joh T
    Hum Pathol; 2018 Apr; 74():92-98. PubMed ID: 29339176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma.
    Ecker BL; Tao AJ; Janssen QP; Walch HS; Court CM; Balachandran VP; Crane CH; D'Angelica MI; Drebin JA; Kingham TP; Soares KC; Iacobuzio-Donahue CA; Vakiani E; Gonen M; O'Reilly EM; Varghese AM; Jarnagin WR; Wei AC
    Clin Cancer Res; 2023 Apr; 29(7):1368-1374. PubMed ID: 36795432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.
    Hingorani SR; Zheng L; Bullock AJ; Seery TE; Harris WP; Sigal DS; Braiteh F; Ritch PS; Zalupski MM; Bahary N; Oberstein PE; Wang-Gillam A; Wu W; Chondros D; Jiang P; Khelifa S; Pu J; Aldrich C; Hendifar AE
    J Clin Oncol; 2018 Feb; 36(4):359-366. PubMed ID: 29232172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.
    Ruess DA; Görgülü K; Wörmann SM; Algül H
    Drugs Aging; 2017 May; 34(5):331-357. PubMed ID: 28349415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies.
    Heinemann V; Reni M; Ychou M; Richel DJ; Macarulla T; Ducreux M
    Cancer Treat Rev; 2014 Feb; 40(1):118-28. PubMed ID: 23849556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
    Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions.
    Zhang Y; Yang C; Cheng H; Fan Z; Huang Q; Lu Y; Fan K; Luo G; Jin K; Wang Z; Liu C; Yu X
    J Hematol Oncol; 2018 Jan; 11(1):14. PubMed ID: 29386069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma.
    Noel M; O'Reilly EM; Wolpin BM; Ryan DP; Bullock AJ; Britten CD; Linehan DC; Belt BA; Gamelin EC; Ganguly B; Yin D; Joh T; Jacobs IA; Taylor CT; Lowery MA
    Invest New Drugs; 2020 Jun; 38(3):800-811. PubMed ID: 31297636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
    Kullmann F; Hartmann A; Stöhr R; Messmann H; Dollinger MM; Trojan J; Fuchs M; Hollerbach S; Harder J; Troppmann M; Kutscheidt A; Endlicher E
    Oncology; 2011; 81(1):3-8. PubMed ID: 21894049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
    Pokorny AMJ; Chin VT; Nagrial AM; Yip D; Chantrill LA
    Intern Med J; 2018 Jun; 48(6):637-644. PubMed ID: 29898269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer.
    Wolfe AR; Robb R; Hegazi A; Abushahin L; Yang L; Shyu DL; Trevino JG; Cruz-Monserrate Z; Jacob JR; Palanichamy K; Chakravarti A; Williams TM
    Clin Cancer Res; 2021 Jan; 27(2):554-565. PubMed ID: 33087331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer.
    Chou A; Froio D; Nagrial AM; Parkin A; Murphy KJ; Chin VT; Wohl D; Steinmann A; Stark R; Drury A; Walters SN; Vennin C; Burgess A; Pinese M; Chantrill LA; Cowley MJ; Molloy TJ; ; Waddell N; Johns A; Grimmond SM; Chang DK; Biankin AV; Sansom OJ; Morton JP; Grey ST; Cox TR; Turchini J; Samra J; Clarke SJ; Timpson P; Gill AJ; Pajic M
    Gut; 2018 Dec; 67(12):2142-2155. PubMed ID: 29080858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of metastatic pancreatic adenocarcinoma: a review.
    Thota R; Pauff JM; Berlin JD
    Oncology (Williston Park); 2014 Jan; 28(1):70-4. PubMed ID: 24683721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial.
    Hoyer K; Hablesreiter R; Inoue Y; Yoshida K; Briest F; Christen F; Kakiuchi N; Yoshizato T; Shiozawa Y; Shiraishi Y; Striefler JK; Bischoff S; Lohneis P; Putter H; Blau O; Keilholz U; Bullinger L; Pelzer U; Hummel M; Riess H; Ogawa S; Sinn M; Damm F
    EBioMedicine; 2021 Apr; 66():103327. PubMed ID: 33862582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
    Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
    Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.